Monoclonal Antibody Facility -MAF The Monoclonal Antibody (MAb) Facility (MAF) provides non-commercially-available antibodies to MD Anderson Cancer Center investigators for specific applications. The MAF serves basic, translational and clinical researchers across the institution and is currently developing projects in each of these three areas. Although the services are based on """"""""traditional"""""""" murine hybridoma technology, the MAF offers custom immunization strategies and support for functional screening in order to produce unique antibodies suitable for novel applications. The MAF occupies 726 sq. ft. in 1SCRB, home to the Center for Cancer Immunology Research (CCIR) on the South Campus. This is a state-of-the-art facility for immunology research that provides a platform for integrating basic and clinical research programs. The CCIR is equipped with customized laboratory services, centralized tissue culture rooms, liquid nitrogen tank rooms, and glassware washing and sterilization facilities, all of which are available to the MAF. The MAF has a tissue culture laboratory (SCR 4.2158), a protein chemistry area (SCR 4.2220), and space in the South Campus Vivarium that is a component of the Research Animal Support Facility shared resource. In the last 5-year period, the MAF developed three MAbs that have potential for clinical development as therapeutic agents, and several additional candidates are in preclinical assessment. Several antibodies produced by the MAF have been licensed or are in the process of being licensed for commercial development. MD Anderson members with peer-reviewed funding accounted for 97% of the usage of the resource and 30% support is requested from the CCSG. Since 2007, the MAF has supported the research of 40 MD Anderson investigators with peer reviewed funding representing 16 CCSG Programs, compared to 13 investigators in the previous grant period. Hybridoma production increased from 44 to 79 projects (a 178% increase), and total services provided increased more than 300% during this grant cycle. Publications cited using the MAF have appeared in Nature, PNAS, Blood and Nature Medicine. Future plans include the purchase of a bioreactor for large-scale production to support the increasing demand for the quantities of MAbs required for preclinical development Novel methods of immunization including DNA expression will be explored. The facility also plans to explore the direct generation of """"""""fully human antibodies"""""""" using """"""""humanized"""""""" mice or using Phage display scFv libraries as a more rapid and direct strategy to produce antibodies for future clinical applications of newly-discovered markers.

Public Health Relevance

The MAF develops high-quality, cost-effective customized MAbs to meet the basic, translational, and clinical research needs of MD Anderson investigators. Rates are comparable to other institutions across the country and, in some cases, significantly lower. Many of the MAbs generated have been licensed or patented.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016672-38
Application #
8557379
Study Section
Subcommittee G - Education (NCI)
Project Start
1998-09-04
Project End
2018-06-30
Budget Start
2013-09-06
Budget End
2014-06-30
Support Year
38
Fiscal Year
2013
Total Cost
$92,283
Indirect Cost
$34,617
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Koyyalagunta, Dhanalakshmi; Bruera, Eduardo; Engle, Mitchell P et al. (2018) Compliance with Opioid Therapy: Distinguishing Clinical Characteristics and Demographics Among Patients with Cancer Pain. Pain Med 19:1469-1477
Liao, Zhongxing; Lee, J Jack; Komaki, Ritsuko et al. (2018) Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 36:1813-1822
Ma, Junsheng; Hobbs, Brian P; Stingo, Francesco C (2018) Integrating genomic signatures for treatment selection with Bayesian predictive failure time models. Stat Methods Med Res 27:2093-2113
Zhu, Hongxiao; Caspers, Philip; Morris, Jeffrey S et al. (2018) A Unified Analysis of Structured Sonar-terrain Data using Bayesian Functional Mixed Models. Technometrics 60:112-123
Li, Jialu; Fu, Chunxiao; Speed, Terence P et al. (2018) Accurate RNA Sequencing From Formalin-Fixed Cancer Tissue To Represent High-Quality Transcriptome From Frozen Tissue. JCO Precis Oncol 2018:
Fujii, Takeo; Colen, Rivka R; Bilen, Mehmet Asim et al. (2018) Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs 36:638-646
Hoover, Diana Stewart; Wetter, David W; Vidrine, Damon J et al. (2018) Enhancing Smoking Risk Communications: The Influence of Health Literacy and Message Content. Ann Behav Med 52:204-215
Franco, Hector L; Nagari, Anusha; Malladi, Venkat S et al. (2018) Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis. Genome Res 28:159-170
Altok, Muammer; Achim, Mary F; Matin, Surena F et al. (2018) A decade of robot-assisted radical prostatectomy training: Time-based metrics and qualitative grading for fellows and residents. Urol Oncol 36:13.e19-13.e25
Patel, Sameer H; Kim, Bradford J; Tzeng, Ching-Wei D et al. (2018) Reduction of Cardiopulmonary/Renal Complications with Serum BNP-Guided Volume Status Management in Posthepatectomy Patients. J Gastrointest Surg 22:467-476

Showing the most recent 10 out of 12418 publications